Cognixion Enrolls 30 ALS Patients in NIH-Funded BCI Trial
Santa Barbara – November 04, 2026 -- Cognixion Corporation is enrolling 30 US adults with amyotrophic lateral sclerosis (ALS) in the CHOICE study, which tests its wearable brain-computer interface (BCI) against the eye-tracking speech devices patients use today. The trial is registered on ClinicalTrials.gov as NCT07871071 and is funded entirely by federal money from the National Institute on Deafness and Other Communication Disorders (NIDCD), part of the National Institutes of Health.
Participants test three communication options at home over 12 weeks
Each participant uses their own eye-tracking speech generating tablet, a head-worn Cognixion BCI with augmented reality display glasses, and a touchscreen-based version of the Cognixion system. Participants choose which option to use in each session. The time they voluntarily spend with each is the study's primary outcome measure.